Details

Autor(en) / Beteiligte

• Deek, Matthew P
• Van der Eecken, Kim
• Sutera, Philip
• Deek, Rebecca A
• Fonteyne, Valérie
• Mendes, Adrianna A
• Decaestecker, Karel
• Kiess, Ana Ponce
• Lumen, Nicolaas
• Phillips, Ryan
• De Bruycker, Aurélie
• Mishra, Mark
• Rana, Zaker
• Molitoris, Jason
• Lambert, Bieke
• Delrue, Louke
• Wang, Hailun
• Lowe, Kathryn
• Verbeke, Sofie
• Van Dorpe, Jo
• Bultijnck, Renée
• Villeirs, Geert
• De Man, Kathia
• Ameye, Filip
• Song, Daniel Y
• DeWeese, Theodore
• Paller, Channing J
• Feng, Felix Y
• Wyatt, Alexander
• Pienta, Kenneth J
• Diehn, Maximillian
• Bentzen, Soren M
• Joniau, Steven
• Vanhaverbeke, Friedl
• De Meerleer, Gert
• Antonarakis, Emmanuel S
• Lotan, Tamara L
• Berlin, Alejandro
• Siva, Shankar
• Ost, Piet
• Tran, Phuoc T

Titel

Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials

Ist Teil von

• Journal of clinical oncology, 2022-10, Vol.40 (29), p.3377-3382

Ort / Verlag

United States: Wolters Kluwer Health

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• JCO The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes of MDT in omCSPC by pooling STOMP and ORIOLE and assess the ability of a high-risk mutational signature to risk stratify outcomes after MDT. The primary end point was progression-free survival (PFS) calculated using the Kaplan-Meier method. High-risk mutations were defined as pathogenic somatic mutations within , / , , or . The median follow-up for the whole group was 52.5 months. Median PFS was prolonged with MDT compared with observation (pooled hazard ratio [HR], 0.44; 95% CI, 0.29 to 0.66; value < .001), with the largest benefit of MDT in patients with a high-risk mutation (HR high-risk, 0.05; HR no high-risk, 0.42; value for interaction: .12). Within the MDT cohort, the PFS was 13.4 months in those without a high-risk mutation, compared with 7.5 months in those with a high-risk mutation (HR, 0.53; 95% CI, 0.25 to 1.11; = .09). Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained clinical benefit to MDT over observation. A high-risk mutational signature may help risk stratify treatment outcomes after MDT.